Cefazolin is a first-generation cephalosporin antibiotic that is typically used for the treatment of bacterial infections. Its impurity profile consists of structurally similar analogs, residual solvents, and degradation products. These impurities can be formed under stress conditions such as hydrolysis, oxidation, and photolysis. Its typical degradation pathways involve oxidative breakdown of the thiazolidine ring, hydrolytic cleavage of the β-lactam bond, and rearrangement of aromatic substituents. These impurities may affect the potency, stability, and safety of the drug. All impurities are structurally characterized and qualified according to ICH guidelines for toxicological assessment and analytical validation.
We provide the pharmacopeial and non-pharmacopeial Cefazolin impurity compounds that are available in compliance with European Pharmacopoeia (EP) specifications. These standards can be used for the support of analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are supplied with validated analytical data, including purity, structural confirmation, and spectral characterization.
Structurally related compounds and synthetic analogs of Cefazolin are included for impurity identification, toxicological qualification, and regulatory submission. These related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.
We provide Cefazolin impurity reference standards with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards can be used in pharmaceutical research, method validation, and GMP-compliant quality control. Also, the EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
